Table 3.
Relationships between lymphoscintigraphic findings and therapy response
| Qualitative lymphoscintigraphic indicators | Dichotomous early response (at 3 months) | Dichotomous late response (at 1 year) | |||||
|---|---|---|---|---|---|---|---|
| Volume increase† | Volume decrease§ | p-value | Volume increase | Volume decrease | p-value | ||
| Inguinal LN uptake | Absent | 4 (57.1%) | 3 (42.9%) | N-S | 4 (57.1%) | 3 (42.9%) | N-S |
| Present | 5 (50.0%) | 5 (50.0%) | 5 (50.0%) | 5 (50.0%) | |||
| Main lymphatic vessel | Absent | 5 (38.5%) | 8 (61.5%) | N-S | 6 (46.2%) | 7 (53.8%) | N-S |
| Present | 4 (100.0%) | 0 (0.0%) | 3 (75.0%) | 1 (25.0%) | |||
| Collateral vessel | Absent | 8 (53.3%) | 7 (46.7%) | N-S | 7 (46.7%) | 8 (53.3%) | N-S |
| Present | 1 (50.0%) | 1 (50.0%) | 2 (100.0%) | 0 (0.0%) | |||
| Dermal backflow (Pattern 1) | Absent | 4 (80.0%) | 1 (20.0%) | N-S | 4 (80.0%) | 1 (20.0%) | N-S |
| Present | 5 (41.7%) | 7 (58.3%) | 5 (41.7%) | 7 (58.3%) | |||
| Dermal backflow (Pattern 2) | Absent OR distal only | 7 (58.3%) | 5 (41.7%) | N-S | 7 (58.3%) | 5 (41.7%) | N-S |
| Proximal only OR whole lower limb | 2 (40.0%) | 3 (60.0%) | 2 (40.0%) | 3 (60.0%) | |||
| Dermal backflow (Pattern 3) | Absent OR proximal only | 6 (85.7%) | 1 (14.3%) | 0.050 | 6 (85.7%) | 1 (14.3%) | 0.050 |
| Distal only OR whole lower limb | 3 (30.0%) | 7 (70.0%) | 3 (30.0%) | 7 (70.0%) | |||
| Dermal backflow (Pattern 4) | Absent OR distal only OR proximal only | 9 (64.3%) | 5 (35.7%) | N-S | 9 (64.3%) | 5 (35.7%) | N-S |
| Whole lower limb | 0 (0.0%) | 3 (100.0%) | 0 (0.0%) | 3 (100.0%) | |||
| Quantitative lymphoscintigraphic indicators | Early response (at 3 months) | Late response (at 1 year) | |||||
|---|---|---|---|---|---|---|---|
| N | Mean rank | p-value | N | Mean rank | p-value | ||
| 1 h LN uptake ratio | Volume increase† | 9 | 8.22 | N-S | 9 | 7.78 | N-S |
| Volume decrease§ | 8 | 9.88 | 8 | 10.38 | |||
| 1 h Extremity uptake ratio | Volume increase | 9 | 7.56 | N-S | 9 | 7.44 | N-S |
| Volume decrease | 8 | 10.63 | 8 | 10.75 | |||
| 1 h Injection site clearance ratio | Volume increase | 9 | 9.56 | N-S | 9 | 9.78 | N-S |
| Volume decrease | 8 | 8.38 | 8 | 8.13 | |||
| 2 h LN uptake ratio | Volume increase | 9 | 8.11 | N-S | 9 | 7.67 | N-S |
| Volume decrease | 8 | 10.00 | 8 | 10.50 | |||
| 2 h Extremity uptake ratio | Volume increase | 9 | 7.33 | N-S | 9 | 6.44 | 0.027* |
| Volume decrease | 8 | 10.88 | 8 | 11.88 | |||
| 2 h Injection site clearance ratio | Volume increase | 9 | 8.22 | N-S | 9 | 8.00 | N-S |
| Volume decrease | 8 | 9.88 | 8 | 10.13 | |||
†Volume difference ratio below zero was considered as volume increase
§Volume difference ratio above zero was considered as volume decrease
*Statistically significant; N-S, not statistically significant